Delivery Order SPE2DB20D2002-SPE2DB26FL00E
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors with a ceiling value of $16,361.85. This firm fixed-price contract, which expires August 21, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procedures with no set-aside designation, and performance...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,435.44 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on September 10, 2025, with completion scheduled for September 11, 2025. This firm fixed-price delivery order represents a non-competitive award issued under DLA's existing contract vehicle with the pharmaceutical distributor. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $16,364.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectors on June 2, 2025. This firm fixed-price delivery order, which is scheduled for completion by June 3, 2025, will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery against AmerisourceBergen's larger pharmaceutical supply contract vehicle with the DLA. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,814.18 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on September 12, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract issued under a...
- The Defense Logistics Agency (DLA) awarded a $14,874.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on August 20, 2025, with an ultimate completion date of August 21, 2025. This non-competitive delivery order was fulfilled from AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle extending through December 2026. The product...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,622.22 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors. This is a firm fixed price, non-set-aside competitive award with a completion date of August 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injectors with a firm fixed price of $12,222.69 and completion deadline of September 23, 2025. This non-competitive delivery order represents a single-unit transaction executed under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle...
- The Defense Logistics Agency (DLA) awarded a $93,571.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on September 9, 2025, with completion targeted for September 10, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and extending through December 2026. The...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB26FL00EDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,553.71 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 mL pen injectors on October 28, 2025, with completion expected by October 29, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order falls under AmerisourceBergen's comprehensive $999.999 billion IDC with DLA Troop Support Medical (contract SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen is a major pharmaceutical distributor providing critical medical supplies including brand-name and generic medications, vaccines, and specialized healthcare commodities to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The current award for Zepbound, a diabetes medication, exemplifies the company's role as a key vendor in the DLA Medical Supply Chain, supporting the full spectrum of pharmaceutical needs across the federal healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.6k | 10/28/25 |